Antibody-Drug Conjugates (ADCs) are a type of targeted cancer therapy that combines an antibody with a cytotoxic drug. The antibody specifically binds to cancer cells, allowing the drug to be delivered directly to the tumor while minimizing damage to healthy cells. This targeted approach enhances the effectiveness of the treatment and reduces side effects. ADCs are designed to improve the precision of cancer treatment by utilizing the unique markers found on tumor cells. Once the antibody attaches to the cancer cell, the cytotoxic drug is released, leading to cell death. This innovative strategy represents a significant advancement in oncology.